(Total Views: 587)
Posted On: 02/25/2017 10:53:43 AM
Post# of 72446
I thought this was interesting opinion in regard to Kevetrin....
Medicine in America is sailing swiftly into a Perfect Storm. As most of us are aware, Paul Ryan is balancing the the removal and replacement of the ACA in one hand and the budget in the other hand. Whether the ACA is replaced or restructured is a hot argument in the halls of Congress and the subject of much debate. Where there is not much conjecture is the need to rein in the projected costs of healthcare in the immediate future. Something will have to be done to insure Medicare and Medicaid will survive in light of an aging American population. This is why President Trump, as one of his first priorities, addressed the CEO's of some of the largest BIO/PHARMAs last month. The focus was starkly obvious...you get drug prices down and we'll help you speed up effective drugs to the market. And what was implied was that those drugs that will receive priority are those that treat Cancer, CNS and Cardiovascular disease. The forecast cost increases from these diseases most threaten the future viability of the Medicare and Medicaid programs.
Medicine in America is sailing swiftly into a Perfect Storm. As most of us are aware, Paul Ryan is balancing the the removal and replacement of the ACA in one hand and the budget in the other hand. Whether the ACA is replaced or restructured is a hot argument in the halls of Congress and the subject of much debate. Where there is not much conjecture is the need to rein in the projected costs of healthcare in the immediate future. Something will have to be done to insure Medicare and Medicaid will survive in light of an aging American population. This is why President Trump, as one of his first priorities, addressed the CEO's of some of the largest BIO/PHARMAs last month. The focus was starkly obvious...you get drug prices down and we'll help you speed up effective drugs to the market. And what was implied was that those drugs that will receive priority are those that treat Cancer, CNS and Cardiovascular disease. The forecast cost increases from these diseases most threaten the future viability of the Medicare and Medicaid programs.
(1)
(0)
